OncoMatch/Clinical Trials/NCT06612944
Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation in Very High-Risk MDS Patients Based on IPSS-M Stratification
Is NCT06612944 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation for myelodysplastic syndromes, adult.
Treatment: Prophylactic Intervention for Relapse Prevention Post-Allogeneic Transplantation — By collecting interventional clinical data to assess the survival and relapse conditions of patients post-transplantation and comparing them with historical data, the primary study endpoint is the 1-year and 2-year relapse-free survival (RFS) post-transplantation. This includes the time from the start of treatment until the documentation of disease progression (bone marrow smear blast cells \> 5% or extramedullary relapse) or death due to any cause, whichever occurs first. This experiment aims to improve the post-transplant survival rates of MDS patients classified as very high risk under the IPSS-M stratification and to explore pathways to prevent relapse.
Check if I qualifyExtracted eligibility criteria
Cancer type
Myelodysplastic Syndrome
Disease stage
Required: Stage VERY HIGH-RISK BY IPSS-M SCORING (IPSS-M)
classified as very high-risk by IPSS-M scoring
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: hematopoietic stem cell transplantation
Lab requirements
Kidney function
serum creatinine ≤ 1.5× uln
Liver function
total bilirubin ≤ 1.5× uln; alt and ast ≤ 2.0× uln
Cardiac function
ejection fraction ≥ 50%
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify